These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 6390450

  • 1. Current status of bladder cancer protocols in the EORTC Genito-Urinary Group.
    Denis L, Pavone-Macaluso M, De Pauw M.
    Prog Clin Biol Res; 1984; 162B():429-39. PubMed ID: 6390450
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Overview of bladder cancer trials in the European Organization for Research and Treatment.
    de Wit R, European Organization for Research and Treatment.
    Cancer; 2003 Apr 15; 97(8 Suppl):2120-6. PubMed ID: 12673705
    [Abstract] [Full Text] [Related]

  • 5. Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Cooperative Group.
    Bono AV, Benvenuti C, Reali L, Pozzi E, Gibba A, Cosciani-Cunico S, Comuzzi U, Anselmo G.
    Prog Clin Biol Res; 1989 Apr 15; 303():533-40. PubMed ID: 2675010
    [No Abstract] [Full Text] [Related]

  • 6. Adjuvant and neoadjuvant therapy for gastric cancer.
    Kelsen DP.
    Semin Oncol; 1996 Jun 15; 23(3):379-89. PubMed ID: 8658222
    [Abstract] [Full Text] [Related]

  • 7. Perspectives for progress in the treatment of superficial bladder cancer. The need for multi-institutional studies and the possible role of the EORTC Genito-Urinary Group.
    Pavone-Macaluso M, Serrette V.
    Prog Clin Biol Res; 1989 Jun 15; 310():357-60. PubMed ID: 2672022
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-term follow-up in superficial transitional cell carcinoma of the bladder: prognostic factors for time to first recurrence, recurrence rate, and survival. Final results of a randomized trial comparing doxorubicin hydrochloride, ethoglucid, and transurethral resection alone. EORTC Genitourinary Tract Cancer Cooperative Group.
    Kurth K, Schroeder FH, Debruyne F, Senge T, Pavone-Macaluso M, de Pauw M, ten Kate F, Sylvester R.
    Prog Clin Biol Res; 1989 Jun 15; 303():481-90. PubMed ID: 2675005
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The integration of chemotherapy, radiotherapy and transurethral surgery in bladder-sparing approaches for patients with invasive tumors.
    Shipley WU, Kaufman DS, Heney NM, Griffin PP, Althausen AF, Prout GR.
    Prog Clin Biol Res; 1990 Jun 15; 353():85-94. PubMed ID: 2217430
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A combined analysis of EORTC/MRC randomized clinical trials for the prophylactic treatment of TaT1 bladder cancer. Eortc Genito-Urinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer.
    Pawinski A, Sylvester R, Bouffioux C, Kurth KH, Parmar M, Bijnens L.
    Acta Urol Belg; 1996 May 15; 64(2):27. PubMed ID: 8701803
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties.
    Choueiri TK, Raghavan D.
    Nat Clin Pract Oncol; 2008 Aug 15; 5(8):444-54. PubMed ID: 18577983
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Bladder cancer clinical trials.
    Lerner SP.
    Urol Oncol; 2005 Aug 15; 23(4):275-9. PubMed ID: 16018944
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.